Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ancient herbal mix could boost liver health in advanced cancer

NCT ID NCT07691645

Disease control Sponsor: Xiang-Qian Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Aug 28, 2026 · Updated 3 times

Summary

This trial tests whether adding a Chinese herbal formula called Shuganhuazhuo to standard anti-cancer therapy can improve liver function and survival in people with advanced hepatocellular carcinoma (the most common type of liver cancer). The study includes 120 adults who are about to start second- or third-line treatment. Half receive the herbal decoction twice daily for six months alongside their regular care; the other half receive standard care alone. Researchers measure liver reserve function using a dye clearance test every two months and track overall survival and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Shuganhuazhuo Formula (Chinese herbal medicine)
What this could lead to
If it works, this could offer a way to protect liver function and extend survival for people with advanced liver cancer who have limited treatment options.
What could go wrong
This is a mid-stage trial with 120 participants, so results are not definitive. Herbal formulas can vary in quality and may interact with other drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2027

An estimate. Start dates often move.

Expected to finish

Aug 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. According to the National Health Commission(China)'s "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2026)", clinically or pathologically diagnosed as primary liver cancer. 2. Barcelona Clinic Liver Cancer (BCLC) stage is C. 3. Planning to receive second-line or third-line anti-tumor therapies. 4. The dominant syndrome in traditional Chinese medicine diagnosis is damp or heat. 5. Age: ≥ 18 years and ≤ 75 years. Exclusion Criteria: 1. Expected survival is less than 3 months. 2. Definitive pathological diagnosis of intrahepatic cholangiocarcinoma or combined hepatocellular-cholangiocarcinoma (cHCC-CCA). 3. Comorbid severe heart, liver, kidney dysfunction: 1. heart * New York Heart Association(NYHA) cardiac function \> class II 2. liver * aspartate aminotransferase \> 3 times the upper limit of normal * alanine aminotransferase \> 3 times the upper limit of normal * bilirubin \> 3 times the upper limit of normal 3. kidney * creatinine clearance (Cockcroft-Gault) \< 60 mL/min) 4. Concurrent with other malignant tumors.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chinese herbal medicine are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chinese herbal medicine HCC - hepatocellular carcinoma Icg (indocyanine green) Overall survival (all-cause mortality) Quality of life

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.